Article and Video CATEGORIES
Immunotherapy for Squamous Non-Small Cell Lung Cancer
Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Hi Ascardino, Welcome to Grace. I'm so sorry to hear of your situation. While we don't have specific info or expertise on ovarian cancer, I did some searching for information. It...
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on
I don't know what to do. No insurance